---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-23-000004"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:46:58.315700+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# AbbVie expects Q4 2022 $243M acquired IPR&D charge, cutting adjusted EPS by $0.14

## Summary
- Q4 2022 acquired IPR&D and milestones expense of $243M pre-tax; $0.14 hit to GAAP and adjusted EPS.
- Q4 2022 adjusted EPS guidance revised to $3.51-$3.55 from prior $3.65-$3.69.
- Full-year 2022 adjusted EPS guidance revised to $13.70-$13.74 from prior $13.84-$13.88.
- Results are preliminary and subject to financial statement closing procedures.
- AbbVie does not forecast acquired IPR&D expense due to transaction uncertainty.

## SEC filing metadata
- accession: 0001551152-23-000004
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000004/0001551152-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000004/abbv-20230106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-23-000004
- JSON: https://secwatch.observer/filing/0001551152-23-000004.json
- Plain text: https://secwatch.observer/filing/0001551152-23-000004.txt

## Key facts
- Earnings Releases
  AbbVie Inc. reported the quarter ended December 31, 2022 results: EPS $3.51 - $3.55. Guidance reaffirmed.
  - Period: the quarter ended December 31, 2022
  - EPS: $3.51 - $3.55
  - Guidance: reaffirmed
  - Result: guidance update
  source text: AbbVie’s fourth quarter 2022 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2022 acquired IPR&D and milestones expense, is $3.51 - $3.55.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000004/0001551152-23-000004-index.htm
- Earnings Releases
  AbbVie Inc. reported the full-year ended December 31, 2022 results: EPS $13.70 - $13.74. Guidance reaffirmed.
  - Period: the full-year ended December 31, 2022
  - EPS: $13.70 - $13.74
  - Guidance: reaffirmed
  - Result: guidance update
  source text: AbbVie’s full-year 2022 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2022 acquired IPR&D and milestones expense, is $13.70 - $13.74.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000004/0001551152-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.